<div id="readability-page-1"><p>Assenagon Asset Management S.A. decreased its position in  Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 76.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 45,600 shares of the biopharmaceutical company's stock after selling 148,100 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Ocular Therapeutix were worth $533,000 at the end of the most recent reporting period.</p><p>A number of other hedge funds have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its position in  Ocular Therapeutix by 44.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after buying an additional 1,600,000 shares in the last quarter.  Deltec Asset Management LLC raised its stake in shares of  Ocular Therapeutix by 2.9% in the second quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company's stock valued at $25,937,000 after acquiring an additional 78,519 shares during the last quarter.  Invesco Ltd. raised its stake in shares of  Ocular Therapeutix by 91.2% in the second quarter. Invesco Ltd. now owns 1,538,846 shares of the biopharmaceutical company's stock valued at $14,280,000 after acquiring an additional 734,017 shares during the last quarter.  Paradigm Biocapital Advisors LP acquired a new position in shares of  Ocular Therapeutix in the 1st quarter worth approximately $9,632,000.  Finally, Raymond James Financial Inc. grew its position in  Ocular Therapeutix by 142.8% during the 2nd quarter. Raymond James Financial Inc. now owns 884,381 shares of the biopharmaceutical company's stock worth $8,207,000 after acquiring an additional 520,138 shares during the last quarter. Institutional investors and hedge funds own  59.21% of the company's stock. </p><div><p><span></span><span>Get <strong>Ocular Therapeutix</strong> alerts:</span></p></div><h2>Insider Activity at Ocular Therapeutix</h2><p>In other Ocular Therapeutix news, insider Peter Kaiser sold 9,653 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total value of $106,472.59. Following the transaction, the insider owned 194,440 shares of the company's stock, valued at approximately $2,144,673.20. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey S. Heier sold 10,502 shares of the firm's stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $11.04, for a total value of $115,942.08. Following the transaction, the insider owned 249,409 shares in the company, valued at approximately $2,753,475.36. This trade represents a 4.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 31,287 shares of company stock worth $359,784. 2.30% of the stock is owned by insiders. </p><h2>Ocular Therapeutix Price Performance</h2><p>Shares of OCUL stock opened at $12.71 on Friday. The firm's 50 day moving average price is $12.28 and its two-hundred day moving average price is $11.67. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.78 and a current ratio of 7.85. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The stock has a market cap of $2.71 billion, a PE ratio of -8.83 and a beta of 0.96. </p><p>Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.02. The company had revenue of $14.54 million during the quarter, compared to analysts' expectations of $14.57 million. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%.  As a group, analysts forecast that  Ocular Therapeutix, Inc. will post -0.98 EPS for the current year. </p><h2>Analysts Set New Price Targets</h2><p>OCUL has been the subject of several research analyst reports. Zacks Research upgraded Ocular Therapeutix from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, October 2nd. Wall Street Zen lowered Ocular Therapeutix from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, December 6th. Needham &amp; Company LLC  reaffirmed a &#34;buy&#34; rating and issued a $20.00 price target on shares of Ocular Therapeutix in a report on Monday, December 8th. HC Wainwright increased their price objective on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, December 8th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Ocular Therapeutix in a research note on Wednesday, October 8th. Twelve equities research analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, Ocular Therapeutix presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $22.56.</p><p><b>Check Out Our Latest Research Report on Ocular Therapeutix</b></p><h2>Ocular Therapeutix Profile</h2> (Free Report)<p>Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.  </p><p>The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Ocular Therapeutix</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Strange Crystal Metal Outperforms Silicon Up to 100X</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NVTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ocular Therapeutix Right Now?</h2><p>Before you consider Ocular Therapeutix, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.</p><p>While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OCUL

<p>Assenagon Asset Management S.A. reduced its stake in Ocular Therapeutix, Inc. by 76.5% in the 3rd quarter, selling 148,100 shares. The fund now holds 45,600 shares worth $533,000. Other hedge funds also adjusted their positions in the company. Insiders sold 31,287 shares worth $359,784 last quarter. Ocular Therapeutix's stock opened at $12.71 on Friday. The company reported a Q3 loss of $0.37 per share, beating estimates by $0.02. Analysts have mixed ratings on the stock.</p>

Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL